CEMI - Chembio stock rises 13% amid plans to develop rapid test for monkeypox
- Chembio Diagnostics ( NASDAQ: CEMI ) said it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test.
- The company added that it is exploring the technical requirements for test development using its technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners.
- "We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are assessing the market needs, timing, regulatory pathway and investment required to develop a test," said Chembio's President and CEO Richard Eberly.
- CEMI +12.64% to $0.98 premarket Aug. 16
For further details see:
Chembio stock rises 13% amid plans to develop rapid test for monkeypox